News
-
Thymosin Alpha-1 Benefits: What Studies Show
Thymosin alpha-1 has a credible immune-modulating mechanism, but its human evidence is condition-specific and mixed. The strongest trials do not support a blanket promise of stronger immunity.
-
Tirzepatide for Weight Loss: What to Know
Tirzepatide for weight loss is a once-weekly prescription treatment studied alongside diet and physical activity. Here is who SURMOUNT-1 enrolled, what it found, and what long-term care involves.
-
BPC-157 Benefits: What the Evidence Actually Shows
BPC-157 has been studied across connective tissue, gut, inflammatory, nerve, and vascular models. The catch is decisive: most findings come from animals or cells, not controlled human trials.
-
Does Semaglutide Expire? Pens, Vials, and BUDs
Yes, semaglutide expires, but the date depends on whether it is an Ozempic pen, a Wegovy single-dose pen, or a compounded vial. The printed expiration date or beyond-use date always wins.
-
Is Semaglutide the Same as Ozempic?
Ozempic is a Novo Nordisk product that contains semaglutide. Compounded semaglutide may name the same base molecule, but it is not Ozempic and the finished products are not interchangeable.
-
Is Tesamorelin FDA Approved? Not Every Form
Egrifta has an indication-specific approval for adults with HIV and lipodystrophy. Tesamorelin offered here is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation is not FDA-approved.
-
KLOW Peptide Benefits: What Each Component Adds
KLOW brings four peptide research rationales into one compounded formulation. The evidence runs from cell studies to animal models, but no clinical trial has tested the finished blend.
-
Semaglutide for Weight Loss: What It Involves
Semaglutide for weight loss is a prescription treatment used alongside lower-calorie eating and physical activity. Its effects build over months, and individual results depend on continued treatment, tolerability, and clinical fit.
-
Sermorelin Injections: Sites and Expectations
Sermorelin is injected into the fatty layer beneath the skin, commonly around bedtime. The dose, schedule, site plan, and storage instructions come from the prescriber and dispensing pharmacy—not a universal online protocol.
-
SS-31 Benefits: What Human Trials Actually Show
The clearest human evidence for SS-31 is narrow: muscle-strength findings in people with Barth syndrome. Larger trials in other mitochondrial, heart, and eye conditions have produced mixed or negative primary results.
-
TB-500 Benefits: What the Evidence Shows
TB-500 benefits are biologically plausible but not established in people. Direct evidence is largely laboratory and animal work on a related actin-binding sequence; the human eye and wound trials tested full-length thymosin beta-4, not systemic TB-500.
-
Tirzepatide Injections: A Practical Guide
Tirzepatide injections deliver prescribed tirzepatide under the skin once weekly. The device may be a prefilled pen, a four-dose KwikPen, or a vial used with a syringe, and each format has its own instructions.
-
Does Semaglutide Cause Depression? What We Know
Large trials, cohort studies, and final FDA and European reviews have not found that semaglutide raises depression or suicidality risk. Individual mood changes still deserve prompt attention.
-
Foods to Avoid on Tirzepatide: A Practical Guide
There is no universal ban list. Smaller portions and fewer fried, high-fat, fizzy, or alcohol-heavy choices may make nausea, reflux, bloating, and fullness easier to manage.
-
GHK-Cu Dosage: How Prescribers Set the Amount
There is no validated human injection dose for GHK-Cu. Topical studies disclose several concentrations, while compounded injection amounts come from clinical practice and must be tied to the exact vial and the person being treated.
-
How Long Do Peptides Take to Work?
Peptide timelines range from hours on a lab test to months on a scale. The useful answer depends on the molecule, the outcome being measured and the quality of the evidence behind it.
-
Peptides With Semaglutide: What the Evidence Says
Evidence gaps depend on the specific peptide combined with semaglutide; [cagrilintide–semaglutide has randomized phase 3 trial data](https://pubmed.ncbi.nlm.nih.gov/40544433/), while the combinations discussed here do not. A provider has to judge each compound on its own evidence, risks, and purpose.
-
Semaglutide and Pancreatitis: What Studies Show
Randomized trials have not shown more acute pancreatitis with semaglutide than with placebo, but the event is rare and remains a prescribing-label warning. Persistent, severe abdominal pain needs prompt medical attention.
-
Semaglutide for Fatty Liver: What Evidence Shows
Semaglutide has strong biopsy-based evidence in adults with MASH and F2–F3 fibrosis. That is narrower than “fatty liver,” and it does not make every semaglutide formulation interchangeable.
-
Thymosin Alpha-1 Side Effects: What Trials Found
Published trials most consistently report local injection-site discomfort; fatigue and rash are uncommon and often hard to attribute. The limits are long-term exposure and the difference between studied thymalfasin and a compounded vial.
Page 10 of 18 · 344 articles